Literature DB >> 26833169

Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats.

Figen Barut1, V Haktan Ozacmak, Inci Turan, Hale Sayan-Ozacmak, Erol Aktunc.   

Abstract

PURPOSE: Multiple organ failure, including acute lung injury, is a common complication of intestinal ischemia and reperfusion (I/R) injury and contributes to its high mortality rate. Activated polymorphonuclear neutrophils and reactive oxygen species contribute to the lung injury caused by intestinal I/R. Mineralocorticoid receptor antagonist spironolactone has a protective effect against I/R injury in animal models of retina, kidney, heart, and brain. The aim of the present study is to investigate the effect of aldosterone receptor blocker spironolactone on lung injury induced by intestinal I/R.
METHODS: Wistar albino rats were divided into four groups: (1) sham control; (2) intestinal I/R (30 min of ischemia by superior mesenteric artery occlusion followed by 3 h of reperfusion); (3) spironolactone pretreatment (20 mg/kg) + I/R; and, (4) spironolactone pretreatment without I/R. Spironolactone was given orally 3 days prior to intestinal I/R. A marker for lipid peroxidation (malondialdehyde; MDA), an indicator or oxidation state (reduced glutathione; GSH), an index of polymorphonuclear neutrophil sequestration (myeloperoxidase; MPO), inducible nitric oxide synthase (iNOS) immunoreactivity, and the histopathology of the lung tissue were analyzed.
RESULTS: Spironolactone pretreatment markedly reduced intestinal I/R-induced lung injury as indicated by histology and MDA and MPO levels. Moreover, the pretreatment decreased the iNOS immunoreactivity.
CONCLUSION: The present study strongly suggests that spironolactone pretreatment decreased neutrophil infiltration, iNOS induction, oxidative stress, and histopathological injury in an experimental model of intestinal I/R induced-lung injury of rats.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26833169     DOI: 10.25011/cim.v39i1.26326

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  7 in total

Review 1.  Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis.

Authors:  Jean Kim; Kyle Miyazaki; Parthav Shah; Landon Kozai; Jakrin Kewcharoen
Journal:  Healthcare (Basel)       Date:  2022-03-30

2.  Perioperative "remote" acute lung injury: recent update.

Authors:  Zhaosheng Jin; Ka Chun Suen; Daqing Ma
Journal:  J Biomed Res       Date:  2017-01-19

3.  Accelerated inflammation and oxidative stress induced by LPS in acute lung injury: Ιnhibition by ST1926.

Authors:  Zewu Dong; Yufang Yuan
Journal:  Int J Mol Med       Date:  2018-03-19       Impact factor: 4.101

Review 4.  COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection.

Authors:  Katarzyna Kotfis; Kacper Lechowicz; Sylwester Drożdżal; Paulina Niedźwiedzka-Rystwej; Tomasz K Wojdacz; Ewelina Grywalska; Jowita Biernawska; Magda Wiśniewska; Miłosz Parczewski
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-17

5.  Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial.

Authors:  Katarzyna Kotfis; Igor Karolak; Kacper Lechowicz; Małgorzata Zegan-Barańska; Agnieszka Pikulska; Paulina Niedźwiedzka-Rystwej; Miłosz Kawa; Jerzy Sieńko; Aleksandra Szylińska; Magda Wiśniewska
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-05

6.  Eplerenone ameliorates lung fibrosis in unilateral ureteral obstruction rats by inhibiting lymphangiogenesis.

Authors:  Ziqian Liu; Cuijuan Zhang; Juan Hao; Gege Chen; Lingjin Liu; Yunzhao Xiong; Yi Chang; Hui Li; Tatsuo Shimosawa; Fan Yang; Qingyou Xu
Journal:  Exp Ther Med       Date:  2022-08-11       Impact factor: 2.751

Review 7.  The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs.

Authors:  Hao Shen; Nu Zhang; Yuqing Liu; Xuerong Yang; Yuanyuan He; Qi Li; Xiaoyan Shen; Yulian Zhu; Yong Yang
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.